Lonza
NEWS
It’s been a busy week so far, with new discovery facilities launched in the biotech space.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
Lonza has been in the process of separating LSI into a standalone unit since 2019.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
Free Lonza webinar to discuss the benefits of using physiologically relevant 3D cell culture models to enhance respiratory research for diseases like COVID-19
“We are extremely motivated to be working hand-in-hand with these premier institutes, among the leaders in cell-based immunotherapy discovery and development, to exhibit the use of the closed, automated Cocoon® Platform for manufacturing cell therapies.
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
Results demonstrating the performance of the eCHO™ Medium will be presented at the 2019 PEGS Europe and Antibody Engineering and Therapeutics conferences
JOBS
IN THE PRESS